Approximately 7,228 bottles of Solifenacin Succinate Tablets (10 mg, 30-count) are being recalled because they were manufactured in violation of Current Good Manufacturing Practice (CGMP) standards. Solifenacin Succinate is a prescription medication used to treat overactive bladder. The recall was initiated because deviations in the manufacturing process mean the product may not meet its required quality and safety standards. Consumers should check their prescription bottles immediately to see if their medication is part of the affected lot.
Manufacturing deviations can lead to inconsistent drug quality, potency, or purity, which may affect the medication's effectiveness or safety. While no specific injuries were reported, products not made according to CGMP standards are considered legally adulterated.
Contact healthcare provider and return to pharmacy
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.